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Abstract
Background: Increasing vascular endothelial growth factor (VEGF) has been reported in remitting symmetrical
seronegative synovitis with pitting edema (RS3PE) syndrome, rheumatoid arthritis (RA), polymyalgia rheumatica
(PMR) and giant cell arteritis (GCA). The aim of this study was to compare VEGF levels in patients over 60 years of
age who have RS3PE, RA, PMR or GCA so as to determine whether elevated VEGF is specific for a rheumatic
disease, the inflammation or edema that occurs with these pathological conditions.
Methods: In this retrospective, multicentric study we assessed serum and plasma levels of VEGF in patients over
60 years of age with rheumatic diseases that were either de novo or of recent onset according to the initial clinical
presentation, and we compared these patients with a control group.
Results: Serum and plasma VEGF levels were determined in 80 patients (5 with RS3PE, 13 with RA, 44 with PMR,
and 18 with GCA) and 37 controls. Edema occurred in five patients with RS3PE, four with RA, and one with PMR,
but not patients with GCA. Serum VEGF levels were significantly higher in individuals with rheumatic diseases
(849 (405.5–1235.5) pg/ml) relative to the controls (484 (302–555) pg/ml) (p < 0.001). There were no significant
differences between patients with RS3PE, RA, PMR, or GCA in terms of the VEGF serum levels (p = 0.60) or
plasma levels (p = 0.57). Similarly, the occurrence of edema did not correlate with VEGF levels.
Conclusion: VEGF increases in rheumatic diseases compared to a control group. This was not associated with
specific rheumatic diseases or with edematous rheumatic diseases.
Keywords: Vascular endothelial growth factor, Rheumatoid arthritis, Polymyalgia rheumatica, Giant cell arteritis,
RS3PE syndrome
Background
Rheumatic diseases in individuals over the age of 60 years
are difficult to diagnose in light of their non-specific
clinical presentation. Polymyalgia rheumatica (PMR),
giant cell arteritis (GCA), and remitting symmetrical
seronegative synovitis with pitting edema (RS3PE) are
pathological conditions that are specific to elderly indi-
viduals, although rheumatoid arthritis (RA) is the most
common of the rheumatic diseases in this population
[1]. While polymyalgia symptoms are seen in PMR [2]
and RS3PE [3], these also occur in 40–60% of patients
with GCA [2] and in an isolated manner in 25% of
patients newly diagnosed with RA [1]. Similarly, while
pitting edema of both hands is ubiquitous in RS3PE [3],
this may be encountered in 12% of patients with PMR
[4], 10% of patients with RA [1], and sometimes in pa-
tients with GCA [2]. Pease et al. performed longitudinal
follow up of 349 patients diagnosed with GCA (n = 57,
(16.5%)), PMR (n = 147, (42%)), or RA (n = 145 (41.5%)),
over a period of at least two years. At the end of this
follow-up period, 10% of the patients were reclassified [5].
Vascular endothelial growth factor (VEGF) is a growth
factor for the vascular endothelium that has key roles in
angiogenesis and vascular permeability. It is synthesized
by various endothelial cells, fibroblasts, smooth muscle
cells, and macrophages, and it accumulates in platelets
[6]. Elevated VEGF has been reported in RS3PE relative
to patients with other connective tissue disorders (such
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as RA, systemic lupus erythematosus, mixed connective
tissue disease, polymyositis, and dermatomyositis) and
healthy individuals, and this can result in edema [7].
The aim of this study was to assess VEGF in patients
over 60 years of age, who had RS3PE, RA that was start-
ing to exhibit symptoms of polymyalgia and/or edema,
PMR, or GCA, so as to determine whether VEGF is spe-
cific to inflammatory pathological change in aged indi-
viduals or to the edema seen with these conditions.
Methods
We carried out a retrospective, multicentric study in two
rheumatology departments and one internal medicine
department. We included patients who were 60 years of
age or older, and who had new or recent onset
(<12 months) rheumatic disease; with RA corresponding
with the criteria for RA according to the American
College of Rheumatology (ACR) 1987 and ACR/European
League Against Rheumatism (EULAR) 2010, PMR accord-
ing to the criteria of Chuang and Hunder, GCA according
to the ACR criteria, or RS3PE according to the McCarthy
description [3]; and in whom serum and/or plasma VEGF
had been determined between the 1 January 2002 and the
31 December 2015. We excluded patients receiving ster-
oidal anti-inflammatory and/or immunosuppressive drugs
and/or biotherapy before the determination of VEGF.
We identified a control group of patients >60 years of
age, who had VEGF determined in the same time period
and who did not have rheumatic disease other than
microcrystalline arthritis. In both groups, we excluded
patients with pathological conditions or health condi-
tions known to involve VEGF, such as the polyneur-
opathy, organomegaly, endocrinopathy, monoclonal
plasma-proliferative disorder, and skin changes (POEMS)
syndrome [8], solid tumors, and hematological malig-
nancies [9, 10]. The characteristics and the laboratory
results for the patients were recorded in their medical
files. Serum and plasma VEGF were determined in
the immunology laboratory of University Hospital
Center of Clermont-Ferrand, FRANCE, using an
immuno-enzymatic method and a kit from RnDSystems:
Quantikine® ELISA. This allowed for quantitative deter-
mination of the VEGF 165 isoform of VEGF A. The nor-
mal range for serum VEGF is 62–707 pg/ml, and for
plasmaVEGF it is lower than 115 pg/ml.
Investigation of the data was approved by the Comité
de Protection des Personnes Sud-Est 6 (number 2015/CE
61), number IRB 00008526 and the Comité de Protection
des Personnes Ouest 6 – 704, the CIC 1412 and the CRB
Santé de Brest BB-0033-00037.
Statistical analysis was performed using Stata software,
version 13 (StataCorp, College Station, TX, USA). The
tests were two-sided, with a type I error set at α = 0.05.
Quantitative data were presented as mean ± standard
deviation or median (interquartile range) according to
statistical distribution (assumption of normality studied
by the Shapiro-Wilk test). Comparisons between the in-
dependent groups (i.e. patients with RA, RS3PE, PMR,
or GCA) were performed by analysis of variance (anova)
or the Kruskal-Wallis (KW) test if the assumptions of
anova were not met (normality, homoscedasticity stud-
ied using the Bartlett test). When appropriate (omnibus
p value <0.05), a suitable post-hoc test was used: Tukey-
Kramer post anova and Dunn post KW. Comparisons of
categorical variables between independent groups were
performed using the chi-squared or Fisher’s exact test,
followed by the Marascuilo procedure for multiple com-
parisons. The study of relationships between quantitative
parameters (VEGF, erythrocyte sedimentation speed, C-
reactive protein (CRP), platelets count) was performed
using Spearman correlation coefficient, according to
statistical distribution of the studied parameters. Last,
random-effect multivariate regression analysis was used to
study the relationship between VEGF and different patho-
logical conditions taking into account adjustment for the
gender and age of the patients, the erythrocyte sedimenta-
tion rate (ESR), and the platelet counts. In these models,
the effect of center was considered as a random-effect.
Results
Eighty patients with rheumatic diseases were assessed
(Table 1). This sample comprised 44 women and 36
men (sex ratio of 1.2) with a mean of 73 years of age.
There were 5 patients diagnosed with RS3PE, 13 with
RA, 44 with PMR, and 18 with GCA. A median delay of
4 months was required for the classification of the
rheumatic disease in nine patients. The median follow-
up duration was 32.67 months (±25.04). There were 65
patients (81.2%) with polymyalgia symptoms, and 10 pa-
tients (12.5%) had an edematous form. The five patients
with RS3PE syndrome were afflicted by symptoms of
polymyalgia and edema. Among the 13 patients with
RA, 5 (38.5%) were seropositive, 2 had erosive disease, 8
(61.5%) had symptoms of polymyalgia, and 4 (30.7%) had
edema. The 44 patients with PMR had polymyalgia symp-
toms and only 1 patient had an edematous form. Out of
the 18 patients with GCA, 14 (77.7%) had a positive tem-
poral artery biopsy, 8 (44.4%) had associated polymyalgia
symptoms, and none had an edematous form.
The control group comprised 37 patients, of whom
25 were women and 13 men (sex ratio of 1.9) with a
mean age of 73 years. They were being monitored for
a monoclonal gammopathy of undetermined signifi-
cance (n = 11), arthrosis (n = 6), a narrowing of the
lumber vertical canal (n = 3), fibromyalgia (n = 3), lumbos-
ciatica (n = 2), microcristalline arthritis (n = 4), peripheral
neuropathy (n = 5), osteoporotic fracture (n = 2), and for
papillitis (n = 1).
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CRP, ESR, the platelet count, and serum VEGF were sig-
nificantly higher (p < 0.001) in individuals with rheumatic
disease than in the controls (Table 1). On the other hand,
there was no difference in plasmaVEGF (p = 0.24).
There were no significant differences in serum
VEGF between patients with RS3PE, RA, PMR, or
GCA (p = 0.60) or in plasma VEGF (p = 0.57) (Table 2).
By multivariate analysis of the patients with rheum-
atic diseases adjusting for sex, ESR, and platelet
count, serum and plasma VEGF did not differ accord-
ing to the rheumatoid diagnosis. There was no differ-
ence in serum VEGF or plasma VEGF in patients
with rheumatic disease with or without edema.
There was positive correlation between serum VEGF
and inflammation markers on the one hand, the ESR
(r = 0.28, p = 0.03) and CRP (r = 0.38, p < 0.002), and
the platelet count (r = 0.47, p < 0.001) on the other
hand. Plasma VEGF, by contrast, was correlated with
CRP (r = 0.30, p = 0.005) (Fig. 1).
Discussion
Our study has shown that serum VEGF increases in
rheumatic disease in elderly individuals irrespective of
the specific diagnosis (i.e. RS3PE, RA, PMR, or GCA)
relative to control subjects. This increase in serum
VEGF could specifically indicate an inflammatory state
as it correlated with increases in ESR, CRP, and the
platelet count, which are all markers of inflammation
[11]. We did not find an association between VEGF and
edematous rheumatic disease.
Making a clinical diagnosis of rheumatic disease in
elderly individuals can prove difficult, particularly with
isolated symptoms of polymyalgia [5]. In a study of three
patients with RS3PE, Arima et al. reported an associ-
ation with serum VEGF levels, with a mean increase of
2,223.3 pg/ml, relative to other connective tissue disor-
ders (such as RA, systemic lupus erythematosus, mixed
connective tissue disease, polymyositis, dermatomyo-
sitis), suggesting that RS3PE can be classified as a VEGF-
associated disorder, which can lead to edema [7].
Another study, assessing serum VEGF in RA identified
higher levels in 22 individuals with RA, with a mean age
of 39 years, relative to 10 healthy subjects (p < 0.01) and
or 10 patients with arthrosis (p < 0.05) [12]. VEGF was
also reported in 29 patients with PMR, relative to 20 age
and gender matched controls. Median serum VEGF
Table 1 Characteristics of patients with a rheumatic disease and the controls
Rheumatic disease (n = 80) Control (n = 37) P value (patients vs controls)
Age, years, mean ± SD 73.05 ± 8.03 73.35 ± 8.55 0.98
Sex, female/male 44/36 24/13 0.31
ESR, mm/h, mean ± SD 65.11 ± 32.01 35.60 ± 25.89 <0.001
CRP, mg/L, mean ± SD 80.79 ± 74.05 12.83 ± 19.92 <0.001
Platelets, Giga/L, mean ± SD 371.89 ± 119.56 262.50 ± 89.59 <0.001
Serum VEGF, pg/ml, median (ITQ) 849 (450.50–1235.50) 484 (308–555) <0.001
Plasma VEGF, pg/ml, median (ITQ) 86 (50.50–148.50) 67 (43–105) 0.16
SD standard deviation, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VEGF vascular endothelial growth factor, ITQ interquartile
Bold is significant value
Table 2 Characteristics and levels of VEGF in the various rheumatic diseases





Age, years, mean ± SD 76.4 ± 9.56 71 ± 7.97 71.41 ± 7.43 76.44 ± 8.07 0.17 76 ± 8.42 72.63 ± 7.95 0.21
Sex, female/male 2/3 8/5 19/25 15/3 0.02a 5/5 39/31 0.74
ESR, mm/h, mean ± SD 50.40 ± 29.84 61.67 ± 39.55 61.24 ± 30.35 82.44 ± 27.34 0.03b 54.89 ± 31.14 66.50 ± 32.10 0.31
CRP, mg/L, mean ± SD 57 ± 35.95 113.62 ± 121.12 73.07 ± 63.11 82.63 ± 62.50 0.81 76.33 ± 54.91 81.38 ± 76.53 0.84
Platelets, Giga/L,
mean ± SD
309.60 ± 58.796 334.33 ± 114.20 313.58 ± 104.71 432.56 ± 96.32 0.03c 314.33 ± 63.69 379.29 ± 123.29 0.12
Serum VEGF, pg/ml,
median (ITQ)
858 (801–1048) 590 (303–1117) 859.5 (413-1386.5) 882 (671–1131) 0.60 953 (712–1927) 844 (436–1160) 0.34
Plasma VEGF, pg/ml,
median (ITQ)
79 (52–94) 90 (47–148) 67 (48–160.5) 120 (69–181) 0.57 108.5 (80.75–146.75) 78 (47–149) 0.58
aSignificant difference (p = 0.02) between PMR and RA on the one hand and PMR and GCA on the other hand; bsignificant difference (p = 0.03) between GCA and
RS3PE on the one hand and GCA and PMR on the other hand; csignificant difference (p = 0.03) between GCA and RA on the one hand and GCA and RS3PE on the
other hand. VEGF vascular endothelial growth factor, RS3PE remitting symmetrical seronegative synovitis with pitting edema, RA rheumatoid arthritis, PMR
polymyalgia rheumatica, GCA giant cell arteritis, SD standard deviation, ITQ interquartile, ESR erythrocyte sedimentation rate, CRP C-reactive protein
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Smets et al. Arthritis Research & Therapy  (2016) 18:283 Page 4 of 6
was 458 (53–1362) pg/ml in the patients and 172
(20–514) pg/ml in the controls (p < 0.001) [13]. In
GCA, Baldini et al. identified an increase in serum
VEGF in 75 patients relative to 24 controls (683.18 ±
69.74 pg/ml vs 226.35 ± 53.66 pg/ml, p < 0.001) and rela-
tive to 15 patients with RA (294.05 ± 56.49 pg/ml, p <
0.039) [14]. Our study is the only one to compare the in-
volvement of serum and plasma VEGF in these rheumatic
diseases (i.e. RS3PE, RA, PMR, and GCA). Unfortunately,
VEGF is not a marker of specific rheumatic disease, as has
been suggested previously. It is also not associated with
edematous rheumatic disease [7].
Discordance between plasma and serum VEGF have
been previously reported [15]. In vitro it has been attrib-
uted to the release of VEGF stored in platelets during
the processing of serum. Thus, as plasma is generally
collected in a tube with anticoagulant, the platelets are
less active and contribute less to the level of VEGF that
is measured [8]. We have found a correlation between
serum VEGF and the platelet count, and such correl-
ation was not seen with plasma VEGF. This is in keeping
with other reports [15]. There remains uncertainty as to
which VEGF measurement is the most relevant. With
POEMS syndromes, where VEGF is a diagnostic criter-
ion, Tokashiki et al. recommend using serum rather than
plasma VEGF, thus, allowing analysis of all of the blood
constituents [15]. However, a degree of variability has
been reported in serum VEGF that is not seen with
plasma VEGF. This could depend on the processing of
the blood, with more pronounced release of VEGF by
platelets depending on the coagulation time of the sam-
ple, and on the analysis technique [8, 15].
One of the limitations of our study is, first of all,
its retrospective nature. Determination of serum and
plasma VEGF is performed routinely in our medical
center in older individuals with inflammatory rheum-
atic disease that is hard to characterize. The studied
population is hence not representative of the rheum-
atic diseases in this age group. In fact our patients
with rheumatic disease mainly have polymyalgia
symptoms (81.2%). Our subgroup of patients with RA
does not include the typical seropositive or erosive
RA, which are easier to diagnose and which represent
70% of RA in elderly individuals [1]. Therefore, the
VEGF results obtained in our patients with RA do
not reflect the actual VEGF levels in patients with
RA who are over 60 years of age.
Conclusions
Our study demonstrates that serum VEGF increases in
elderly patients with inflammatory rheumatic disease
compared to a control group. This is neither associated
with specific rheumatic diseases nor with edematous
rheumatic disease. Our results only indicate that VEGF
is a parameter associated with inflammation.
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Fig. 1 Correlation between serum and plasma vascular endothelial growth factor (VEGF) and the markers of inflammation, erythrocyte sedimentation
rate (ESR) (a), C-reactive protein (CRP) (b), and platelets (c) in the 117 patients in the study. a Plasma VEGF and ESR (r = 0.12, p = 0.34), and serum VEGF
and ESR (r = 0.31, p = 0.003). b Plasma VEGF and CRP (r = 0.30, p = 0.005), and serum VEGF and CRP (r = 0.51, p < 0.001). c Plasma VEGF and platelets
(r = 0.20, p = 0.06), and serum VEGF and platelets (r = 0.50, p < 0.001)
Smets et al. Arthritis Research & Therapy  (2016) 18:283 Page 5 of 6
References
1. Soubrier M, Tatar Z, Couderc M, Mathieu S, Dubost JJ. Rheumatoid arthritis
in the elderly in the era of tight control. Drugs Aging. 2013;30:863–9.
2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell
arteritis. Lancet. 2008;372:234–45.
3. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis
with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis
Rheum. 2010;40:89–94.
4. Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al.
Erythrocyte sedimentation rate and C-reactive protein in the evaluation of
disease activity and severity in polymyalgia rheumatica: a prospective
follow-up study. Semin Arthritis Rheum. 2000;30:17–24.
5. Pease CT, Haugeberg G, Morgan AW, Montague B, Hensor EM, Bhakta BB.
Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and
temporal arteritis in patients presenting with polymyalgic symptoms. A
prospective longterm evaluation. J Rheumatol. 2005;32:1043–6.
6. Plate KH, Warnke PC. Vascular endothelial growth factor. J Neurooncol.
1997;35:365–72.
7. Arima K, Origuchi T, Tamai M, Iwanaga N, Izumi Y, Huang M, et al. RS3PE
syndrome presenting as vascular endothelial growth factor associated
disorder. Ann Rheum Dis. 2005;64:1653–5.
8. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-
stratification, and management. Am J Hematol. 2011;86:591–601.
9. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and
metastasis–correlation in invasive breast carcinoma. N Engl J Med.
1991;324:1–8.
10. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al.
Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581–90.
11. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
inflammation. N Engl J Med. 1999;340:448–54.
12. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T,
et al. Vascular endothelial growth factor in patients with rheumatoid
arthritis. Scand J Rheumatol. 1998;27:377–80.
13. Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, et al.
Vascular endothelial growth factor production in polymyalgia rheumatica.
Arthritis Rheum. 2000;43:2472–80.
14. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-
Gonzalez S, et al. Selective up-regulation of the soluble pattern-recognition
receptor pentraxin 3 and of vascular endothelial growth factor in giant cell
arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum.
2012;64:854–65.
15. Tokashiki T, Hashiguchi T, Arimura K, Eiraku N, Maruyama I, Osame M.
Predictive value of serial platelet count and VEGF determination for the
management of DIC in the Crow-Fukase (POEMS) syndrome. Intern Med.
2003;42:1240–3.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Smets et al. Arthritis Research & Therapy  (2016) 18:283 Page 6 of 6
